Paclitaxel Binding to Human and Murine MD-2

Abstract

Paclitaxel (PTX) is an important cancer chemotherapeutic agent that binds to ␤-tubulin and prevents mitosis through microtubule overstabilization. Recent evidence also implicates PTX in the induction of apoptosis of cancer cells via the TLR4 innate immune pathway. The TLR4 accessory protein, MD-2, is an essential component for the species-specific proinflammatory activity of PTX on murine cells. However, whether PTX binds to human MD-2 and how MD-2 and TLR4 interact with PTX are not well defined. Recombinant human MD-2 (rhMD-2) was produced in a Pichia pastoris expression system, and the interaction between rhMD-2 and PTX was assessed by an enzyme-linked immunosorbent assay to show that PTX binds rhMD-2. Formation of the latter complex was found to be dose-dependent and inhibited by anti-MD-2 antibody but not by an isotype control antibody. As measured by human tumor necrosis factor ␣ production, human THP-1 monocytes expressing TLR4 and MD-2 were poorly responsive to the addition of PTX, but murine macrophages expressing TLR4 and MD-2 responded in a dose-dependent manner. Human embryonic kidney (HEK293) cells transfected with both human TLR4 and human MD-2 or human MD-2 and murine TLR4 were also poorly responsive to PTX (10 M). However, HEK293 cells transfected with murine MD-2 and human TLR4 or murine MD-2 and murine TLR4 were highly responsive to PTX (10 M), indicating that the murine MD-2/PTX interaction is required for TLR4 activation. To further define the structural differences for MD-2/TLR4 activation, crystal structures of both murine and human MD-2 were subjected to PTX docking by computational methods. These models indicate that PTX binds in the pocket of both human and mouse MD-2 structures. The species-specific difference between human and murine MD-2 activation of TLR4 by PTX can be explained by alterations of surface charge distribution (i.e. electrostatic potential), binding pocket size, and the locus of PTX binding within the MD-2 pocket, which results in reorganization of the 123-130 amino acid loop. In particular, Phe 126 appears to operate as a bridge for TLR4⅐MD-2 dimerization in the mouse but not the human protein. Paclitaxel (PTX)3 (Fig. 1) is a potent anti-cancer agent derived from the Pacific yew tree, which acts through overstabilization of cellular microtubules. The natural product leads to disruption of mitotic machinery and inhibition of cell growth (1-3). Structurally, the PTX molecule and its interaction with ␤-tubulin have been well characterized (4 -6). PTX also exhibits antiangiogenic properties, and these have expanded the application of the family of drugs known as taxanes to a variety of tumor types (breast, prostate, ovarian, lung) (7) and to treatment of coronary atherosclerosis via paclitaxel-coated coronary stents (8). The contribution of innate immunity pathways to the mechanism of action of PTX has not been well studied. However, the wide ranging applications of this family of drugs and the known interaction of PTX with TLR4 (Toll-like receptor 4) (9, 10) suggest a pote...

Tetraacylated Lipid A and Paclitaxel-Selective Activation of TLR4/MD-2 Conferred through Hydrophobic Interactions

“…Differences in the electrostatic potential of MD-2, hydrophobicity, and binding pocket size have been proposed to be responsible for the species-specific activation of TLR4 by paclitaxel (31). The apparently similar functional TLR4 agonist properties of lipid IVa and paclitaxel are striking given the completely different structure of these two compounds (Fig.…”

A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer

“…Some studies have reported a role of ROS in Taxol-induced cytotoxicity (39). However, the bulk of the literature established that Taxol interaction with microtubules (through stabilization of microtubule-associated proteins) is a key mechanism of Taxol function (40)(41)(42)(43). Therefore, we hypothesize that non-ROS mechanisms such as inhibition of the proangiogenic or proinflammatory signaling of HO-1 by OB-24 may contribute to the synergistic activity observed.…”

Paclitaxel Ameliorates Lipopolysaccharide-Induced Kidney Injury by Binding Myeloid Differentiation Protein-2 to Block Toll-Like Receptor 4–Mediated Nuclear Factor-κB Activation and Cytokine Production

“…LPS is the primary ligand of Toll-like receptor 4 (TLR4), activating it through binding to its accessory protein myeloid differentiation protein-2 (MD-2) (Shimazu et al, 1999;Akashi et al, 2000). Interestingly, in in vitro binding assays, paclitaxel was shown to bind human and murine MD-2 (Zimmer et al, 2008). In view of these findings, this study was initiated to assess whether low doses of paclitaxel can block TLR4-mediated NF-kB signaling by binding to MD-2 leading to the attenuation of LPS-induced AKI.…”